|
subsections menu :
Contacts
|
Content :
2004 R&D Press releasesDecember 20, 2004 Sanofi-aventis receives Patent Office’s Notice of Allowance on its reissuance application for Lovenox ‘618 patent.
November 9, 2004 Aventis, part of the sanofi-aventis Group, announced termination of its agreements with Genta
November 5, 2004 Eloxatin™ (oxaliplatin for injection) receives FDA approval for the treatment of colon cancer following surgery (adjuvant treatment)
November 4, 2004 European Union Approval for Taxotere® (docetaxel) in Prostate Cancer
October 26, 2004 Aventis Receives Approvable Letter from U.S. Food and Drug Administration for Alvesco® (ciclesonide) for Treatment of Persistent Asthma
September 17, 2004 Eloxatin® to receive expanded indication in Europe for early stage colorectal cancer treatment
|
Slots : |
